Vaccination therapies constitute potential treatment options in neurodegenerative disorders such as Alzheimer disease or Parkinson disease. While a lot of research has been performed on vaccination against extracellular amyloid b, the focus recently shifted toward vaccination against the intracellular proteins tau and a-synuclein, with promising results in terms of protein accumulation reduction. In this review, we briefly summarize lessons to be learned from clinical vaccination trials in Alzheimer disease that target amyloid b. We then focus on tau and a-synuclein. For both proteins, we provide important data on protein immunogenicity, and put them into context with data available from both animals and human vaccination trials targeted at tau and a-synuclein. Together, we give a comprehensive overview about current clinical data, and discuss associated problems.
with APO E4 being by far the most prominent one. Pathophysiologically, AD is characterized by both extracellular depositions of Ab as well as intracellular tau depositions that form neurofibrillary tangles (NFT) in neurons (Querfurth and LaFerla 2010) . Clinically, patients slowly develop cognitive impairment. Disease progression increasingly affects short-term memory, language and executive functions including visuospatial perception (Karantzoulis and Galvin 2011) . The group of frontotemporal dementia (FTD) spectrum disorders constitutes another form of dementia, which in part overlaps with amyotrophic lateral sclerosis. The initial description of FTD described an early-onset dementia with changes in behavior, language, and executive control. Imaging and autopsies revealed prominent frontal lobe atrophy in the patients' brains. Today, some subgroups of these heterogeneous disorders are genetically described. Known mutations are in the MAPT gene coding for the microtubule-associated protein tau, the GRN gene coding for progranulin, the TARDBP gene coding for the tar-DNA binding protein TDP-43, and C9ORF72 coding for the C9orf72 protein causing the overlap to amyotrophic lateral sclerosis (Loy et al. 2014) .
In PD, the second most common neurodegenerative disorder, the formation of a-synuclein (a-syn) deposits is a major hallmark of the disease. The incidence of PD increases progressively with age: While about 1% of the individuals aged 65 years are affected, the rate increases to 5% or more in individuals who are 85 years and older (Lee and Trojanowski 2006) . Genetic mutations can lead to familial PD syndromes. Examples are SNCA, PARKIN, PINK1, and LRRK2 and other genes whose mutant forms increase the risk of developing PD [for review see (Abeliovich and Gitler 2016) ]. For example, patients carrying mutations of the bglucocerebrosidase gene (GBA1) show an increased risk of developing PD (Blanz and Saftig 2016; Migdalska-Richards and Schapira 2016) . The clinical symptoms were first described by James Parkinson in 'An Assay on the shaking Palsy' in 1817 and include akinesia, rigidity, and tremor at rest (Parkinson 1817) . Nevertheless, a pre-symptomatic period of several years if not more precedes disease onset (Oertel and Schulz 2016) . In addition to the typical motor symptoms, PD encompasses a variety of non-motor symptoms such as autonomic dysfunction, sensory abnormalities, and psychiatric abnormalities including dementia (Ferrer 2011) . PD treatment includes L-Dopa, dopamine agonists, inhibitors of dopamine degradation as well as deep brain stimulation (Oertel and Schulz 2016) .
a-syn is a natively unfolded protein with a length of 140 amino acids, localized in the presynaptic terminals. It is predominantly expressed in the neurons of the neocortex, hippocampus, substantia nigra, thalamus, and cerebellum (Spillantini et al. 1997) . In PD patients, neurons show characteristic cytoplasmic inclusions, the so-called Lewy bodies. Fibrillary a-syn is the main component of protein aggregates within Lewy bodies and Lewy neurites (Spillantini et al. 1997) . a-syn deposits are not only found in the substantia nigra. Braak was the first to describe the spread of a-syn pathology in six characteristic stages along anatomical connections (Braak et al. 2003) . Braak postulated that aggregated a-syn could rise from the gut and spread via the vagal gut-brain connection to the brain. This hypothesis is supported by the presence of a-syn aggregates in the gut autonomous neural system (Braak et al. 2006; Shannon et al. 2012 ). The hypothesis is further supported by rat experiments, in which rats developed a-syn deposits in the dorsal motor nucleus of the vagus in the brainstem following a-syn injection into the intestinal wall (Holmqvist et al. 2014) . In an environmental toxin-induced PD mice model, a ligation of the vagal nerve could stop disease progression ipsilaterally (Pan-Montojo et al. 2012) . The same seems to hold true in humans, as a cohort study reported a reduced risk to develop PD in patients who underwent truncal vagotomy (Svensson et al. 2015) . For a comprehensive review on evidence for the PD progression via the 'gut-brain-axis', see Klingelhoefer and Reichmann (2015) . Cell-to-cell spreading of a-syn is the driving force for disease progression at least in mice as demonstrated by Luk (Luk et al. 2012) . Different conformational forms contribute to disease progression: Oligomers and protofibrils as well as non-fibrillary a-syn inclusions or aggregates seem to trigger motor impairment (Hashimoto et al. 2003) . Additionally, different a-syn strains are thought to promote distinct synucleinopathies (Peelaerts et al. 2015) .
Besides the formation of pathogenic protein aggregates, both AD and PD share another important feature: The disease process begins decades before the clinical manifestation of the first symptoms. For AD, it is believed that formation of Ab and tau oligomers starts 20 years before memory deficits become apparent (Bateman et al. 2012 ). The time period in which patients develop AD pathology in the brain, but do not yet show any symptoms, is called the pre-symptomatic phase. This stage is followed by a prodromal phase, in which patients are afflicted with mild cognitive impairments, and ultimately culminate in dementia with deficits in multiple domains (Trojanowski et al. 2010) . In PD, there is likewise a prodromal stage, which is characterized by hyposmia, REMsleep behavior disorder (RBD), constipation, and depression (Berg et al. 2015) . The lack of reliable biomarkers to identify prodromal stages renders it difficult to study diseasemodifying drugs in prodromal patients. There is an urgent need to determine biomarkers either in CSF or using imaging methods to identify patients in the prodromal stage. Such biomarkers should then be suited ideally to monitor disease progression as well.
Learning lessons from vaccination in AD
In the past 20 years, different immunization strategies against Ab have been pursued. We will briefly summarize exemplary data. The interested reader may refer to Table 1 that summarizes clinical trials against Ab. The first immunization approach against Ab was performed by Schenk and coworkers in PDAPP mice that over-express a mutant human Ab variant (Schenk et al. 1999) . Encouraged by the promising results, a multinational phase II trial (NCT00021723) was initiated in patients with mild to moderate AD and enrolled 372 subjects. Unfortunately, 19 patients treated with active vaccination developed brain inflammation because of aseptic meningoencephalitis, which led to the discontinuation of the study and the associated vaccine development in 2002 (Robinson et al. 2004) . The meningitis was probably of autoimmune origin, mediated by an overwhelming Th1 helper cell stimulation (Tabira 2010) . In succession, active vaccines were developed that avoided Th1 helper cell stimulation. Passive immunization completely bypasses the problem and led to the development of many different compounds.
In the following, we exemplary highlight lessons learned from three monoclonal antibodies -bapineuzumab, solanezumab, and aducanumab -that however stand for many other compounds that are currently under clinical investigation. Bapineuzumab is a humanized monoclonal antibody that recognizes Ab at the N-terminus (Salloway et al. 2009 (Salloway et al. , 2014 . It has been studied in two large phase III studies. More than 2400 patients with mild to moderate AD were treated for 18 months with either the antibody or a placebo, but cognitive decline was not influenced by treatment (Salloway et al. 2014 ). However, a mild effect was measured in biomarkers in both cerebrospinal fluid (CSF) and positron emission tomography (PET) scan. Some patients exhibited imaging abnormalities following immunization against Ab. These magnetic resonance imaging signal abnormalities, called amyloid-related imaging abnormalities (ARIA), were suggestive of vasogenic edema and microhemorrhages with hemosiderin deposits. It is not entirely clear whether ARIA have to be regarded as an adverse effect, but they seem to be a class-defining phenomenon. For bapineuzumab, ARIA was described as a spectrum of imaging findings with variable clinical correlates (Sperling et al. 2012) . The risk of ARIA increased among APO E4 carriers, and there was an association between ARIA and alterations in vascular amyloid burden. Nevertheless, some patients with ARIA remained asymptomatic even if treatment with bapineuzumab was continued (Sperling et al. 2012) .
A second antibody, solanezumab, was tested in three phase III studies (EXPEDITION I-III). Antibody treatment did not lead to cognitive improvement in patients with either mild or moderate AD. Further analysis showed that patients with mild AD might benefit from the antibody treatment (Doody et al. 2014) . Consequently, treatment with solanezumab was tested in patients with only mild AD. However, press releases of the company indicated that solanezumab did not lead to improvement of cognition in patients with mild AD over a time period of 18-month placebo-controlled period followed by an open label extension (Lilly 2016) . Obviously, patients with advanced disease and possibly even mild clinically diagnosed AD are unsuited for Ab-targeted drug trials. Only in the latest study, however, the AD diagnosis of patients was not biomarker confirmed. As AD pathology starts more than 20 years prior to clinical symptoms, current trials include patients with prodromal or mild AD for an earlier intervention. Furthermore, the focus for selection criteria for patients moves from clinical and neuropsychological markers toward additional biomarkers for stratification (e.g., CSF amyloid, tau and phospho-tau concentrations or amyloid PET), and genetic characteristics (e.g., APO E status). Measurement of AD-specific biomarkers was not mandatory in the majority of the studies described above. However, retrospective data analysis reveals that up to 30% of patients included in recent AD trials did not have a positive amyloid PET scan indicative of AD pathology (Scheltens et al. 2016 ). Nowadays, studies are being designed to start therapy in patients with prodromal AD, and the determination of amyloid biomarkers is mandatory for enrolment into the study. The most promising antibody so far is aducanumab, a naturally occurring antibody against Ab. It was developed by isolating B cells from healthy aged donors. These B-cells were single cell sorted and incubated with Ab. B-cells proliferating after exposure with Ab were selected and antibodies were Evidence before research, search strategy, and selection criteria Vaccination therapies constitute potential treatment options in neurodegenerative disorders such as Alzheimer disease or Parkinson's disease. In this review, we summarize current vaccination strategies against the intracellular proteins tau and a-synuclein from both animal and human vaccination trials. In addition, we comment on lessons learned from clinical vaccination trials in Alzheimer disease targeting amyloid b and discuss potential mechanisms of action. We searched PubMed between 01/01/1999 and 20/03/2017 using the terms 'Alzheimer 0 s Disease' or 'Parkinson 0 s Disease' in combination with 'immunization', 'active', 'passive', 'amyloid b', 'tau', 'asynuclein', and 'naturally occurring autoantibodies'. Furthermore, we searched clinicaltrials.gov. If there were no entries, we checked ISRCTN registry and clinicaltrialsregister.eu. Further valuable information was obtained from alzforum.org. We searched the categories 'target type' for amyloid, tau-related, and a-syn, 'therapy' for immunization and 'condition' for AD and PD. Articles were also identified through searches of the authors' own files. Additional articles were included from reference lists and review articles. We only reviewed studies published in English or German. The final reference list was generated on the basis of originality and relevance to the topics covered in this review. Emphasis was placed on publications from the past 10 years, but we did not exclude commonly referenced and highly regarded older publications. sequenced. The most promising clone in vitro was then taken into the clinical study. In a first dose-finding phase Ib/IIa study in patients with prodromal to mild AD, aducanumab led to a concentration-dependent reduction of cerebral Ab plaque load as measured by florbetapir PET over a time period of 54 weeks (Sevigny et al. 2016) . Although the number of included patients was low, cognitive decline was significantly and dose dependently slowed down at week 54. This antibody is currently tested in two large phase III studies (ENGAGE, EMERGE) and results are awaited eagerly by researchers and patients alike.
Naturally occurring autoantibodies Naturally occurring antibodies (nAbs) are part of the innate immune system. They are produced without contact to the specific antigen they recognize, and are polyclonal (Kasaian and Casali 1993) . Most evidence concerning nAbs is available for nAbs against Ab and is summarized in a review by Bach and Dodel (2012) . Already in 1993, nAbs were described in AD patients (Gaskin et al. 1993) . In 2001, Du et al. detected significantly decreased levels of nAbs against Ab in the CSF of AD patients. With a tissue microarray comparing 48 AD patients with 48 age-matched healthy controls, it was proven that nAbs bind specifically to neuritic plaques (Kellner et al. 2009) , and that patients with a high load of immunoglobulin G (IgG)-positive plaques had a lower plaque load and higher microglial activity. nAbs-Ab were detected in immunoglobulins (IVIg) as described by Dodel (Dodel et al. 2002) . nAbsAb were reduced in patients suffering from AD (Dodel et al. 2004) . nAbs against Ab from IVIg seem to dissolve preformed fibrils and increase microglial migration and phagocytosis (Istrin et al. 2006; Gold et al. 2013; Mengel et al. 2013) . nAbs against Ab predominantly bind to the Cterminal epitope (Dodel et al. 2011 ) and seem to recognize conformational epitopes in oligomers and fibrils rather than sequence-specific epitopes (O'Nuallain et al. 2008) . To test the hypothesis that nAbs play a role in Ab degradation, clinical trials with IVIg were initiated in AD patients. In two pilot studies with only five to eight patients for 6-15 months, treatment with IVIgs resulted in cognitive improvement in patients with AD (Dodel et al. 2004; Relkin et al. 2009 ). These data expedited a large phase III study in patients with mild to moderate AD. However, cognition remained comparable between patients in the placebo and the IVIg groups (Loeffler 2013) . While IVIgs may act through different mechanisms, the main reason for their efficacy and probably the reason for the lack of effect in IVIg studies is the low concentration of naturally occurring antibodies against Ab in IVIg ( Dodel et al. 2004 ) that is probably too low to trigger measurable effects at the cognitive level. Therefore, sufficient concentrations may only be achieved with monoclonal antibodies as they are employed in current clinical trials. Variation in specific nAbs levels has also been described for a-syn and tau. PD patients have lower levels of a-synspecific nAbs (Besong-Agbo et al. 2013) , and nAbs against tau are reduced in patients with PD dementia (Kronimus et al. 2016) . Two monoclonal antibodies resembling nAbs are available in clinical studies: the first one is aducanumab (see above), the second one is BIIB0054 (see Passive immunization against a-syn in humans).
In this review, we would like to give a comprehensive overview of the target proteins tau and a-syn in neurodegenerative disorders and current data and literature of active and passive immunization strategies in animal and human studies. We will not discuss Ab in more depth, since therapies directing amyloid have been reviewed in depth and it would be beyond the scope of this review.
Tau-based therapies
Characteristics of tau protein Many researchers target tau or phosphorylated tau as an antigen in AD and in the group of tauopathies, including variants of FTD and progressive supranuclear palsy (PSP) (Armstrong et al. 2007; Riedl et al. 2014) . Tau consists of minimum 351 or maximum 441 amino acids and occurs in multiple variants because of alternative splicing. It is encoded by the MAPT gene on chromosome 17. There are six isoforms in the brain (Goedert et al. 1989a) . The protein can display zero, one, or two inserts at the N-terminus coded by exons 2 and 3. The second variation results from the presence of either three or four repeat regions at the Cterminal part encoded by exon 10 that comprises the microtubule-binding domain (Goedert et al. 1989b) . Under physiologic conditions, tau is required for microtubule assembly and stability. The main function of tau is the stabilization of microtubules, hence the name tubulin-binding protein (Mandelkow et al. 2007) . In AD, hyperphosphorylation at the paired helical filament epitope 1 (PHF1) at Ser396 and Ser404 leads to a pathologic change in protein conformation (Jeganathan et al. 2008) . This results in tau aggregation, and disruption of microtubules and the cytoskeleton (Alonso et al. 1996) finally leading to the formation of neurofibrillary tangles (Mandelkow and Mandelkow 2012) . The distribution of these NFT correlates well with the stages of dementia in AD (Goedert 2004) . Because of its size and the multiple splice variants, tau is a challenging epitope for vaccination studies. A detailed description of the protein and important regions for immunization are illustrated in Fig. 2 .
Active immunization against tau in animals
In 2006, the first active immunization against tau was published. The authors immunized wild-type C57BL/6 immunocompetent laboratory mouse strain mice with 50 lg of recombinant human tau protein (Rosenmann et al. 2006) . This triggered prominent motor symptoms caused by inflammatory microglial activation and increased fibril deposition. In part, the authors explained the strong inflammatory response by a very strong adjuvant (complete Freund's adjuvant and pertussis toxin). In this case, pertussis toxin likely led to increased blood-brain barrier permeability. No correlation was detected between onset and severity of motor symptoms and tau antibody levels (Rosenmann et al. 2006) . Upon repeated vaccination, inflammatory effects were even stronger (Rozenstein-Tsalkovich et al. 2013) . The authors found encephalitis-like symptoms in about 75% of their mice after seven injections in adult animals. In a subgroup of older mice, this effect was less prominent. Vaccination-induced immunoreaction seemed to have been excessive and may have led to accelerated cell death (Wisniewski and Goni 2015) . Later on, the Rosenmann group developed a vaccine consisting of phosphorylated tau peptides (Boimel et al. 2010) . They immunized mice that express human tau with three different peptides: tau195-213 [P 202/205 ], tau207-220[P 212/214 ], and tau224-238 [P 232 ]. Tau mice expressing a human 383-amino acid-long isoform with mutated P301S usually develop motor symptoms at the age of about 5-6 months (Allen et al. 2002) . To enhance tau pathology in these mice, the authors combined their model with an experimental autoimmune encephalomyelitis model (experimental autoimmune encephalomyelitis). This led to detectable tau pathology at the age of 2-4 months. Immunized animals showed a decrease in tau burden (Boimel et al. 2010) . The authors found a decrease in lysosomal markers cathepsin D and L. Nevertheless, they postulated that the lysosomal system accounted for the decrease in tau burden. In spite of the autoimmunogenic enhancement in their model, they found no signs of encephalitis (Boimel et al. 2010) . In 2007, Asuni and coworkers claimed the first proof-ofconcept study for tau immunization (Asuni et al. 2007) . They used the tau peptide 379-408 with phosphorylated serine 396/404 to immunize P301L tau transgenic mice. Hundred microgram of the phosphopeptide together with an aluminum adjuvant were administered subcutaneously on days 1 and 14 followed by monthly injections. They detected a strong induction of immunogen-specific antibodies. Histological assessment revealed a reduction of tau pathology in the dentate gyrus, motor cortex, and brainstem. In motor and memory tests, immunized mice performed better. Mechanistically, the authors assumed a switch from insoluble tau to soluble tau in immunized mice, possibly pointing to an increase in tau degradation (Asuni et al. 2007 ). In a followup study, the group tested the same immunogen in a different mouse model that co-expressed all six human tau isoforms and the M146L presenilin mutation on a null tau mouse background (Boutajangout et al. 2010) . Although the mechanism of how presenilin enhances tau pathology remains unclear, these mice showed an earlier onset and a more aggressive progression of tau pathology and memory deficits, starting at about 2 months of age. Immunization prevented memory deficits in three different cognitive tests and reduced pathological tau levels in the brains of immunized mice as compared to non-treated mice (Boutajangout et al. 2010) . A shorter tau phosphopeptide with the same phosphorylation sites was tested in tau P301L mice. Theunis et al. immunized with phosphorylated tau 393-408 (pS396/pS404) and obtained similar results with respect to immunogenicity and motor improvement (Theunis et al. 2013) . They used a liposomal-based immunogen preparation (ACI-35) which forms bilayers via N-and C-terminal palmitoylated lysine residues. The epitope consisted of a 16-mer synthetic peptide corresponding to human Tau sequence 393-408 with phosphorylation at S396 and S404. Immune responses of peripheral T-cell splenocytes of mice immunized with the liposomal tau peptide were compared with full-length tau with an aluminum hydroxide adjuvant. The liposomal vaccine generated a specific immune response directed toward the vaccine peptide. Treated mice had less tau and phosphorylated tau deposition in forebrain and brainstem, and performed better in motor tasks (clasping score) and slightly better on the Rotarod. Furthermore, ACI-35 vaccination prevented weight loss that P301L mice suffer from in later stages. Interestingly, the full-length tau vaccine resulted in interleukin 4 and interferon gamma-c secretion upon restimulation with the tau peptide variants. The authors interpreted these findings as a possible explanation for the prominent inflammatory reaction described by Rosenmann (Rosenmann et al. 2006; Theunis et al. 2013) . Untreated P301L-mutant mice suffered from severe symptoms in later stages and died at the age of 8-11 months. Immunization with ACI-35 prolonged the overall survival compared to untreated mutant mice (Theunis et al. 2013) . Selenica et al. (2014) immunized rTg4510 tau mice with a milder, saponine-based adjuvant. Their immunogens consisted of a human full-length tau or P301L tau. They reported an increased cellular immune response, whereas tau levels and neuroinflammation were both reduced, in the absence of adverse events. In mouse brain, they found a decrease in neuroinflammation that reflected in lower counts of leucocytes (CD45) and microglial activation markers (CD11b). Nevertheless, the cellular immune response in splenocytes was increased. With the help of a peptide array assay, the authors identified five formerly unknown immunogenic motifs in the tau protein, offering different immunization strategies. Kontsekova et al. (2014) described a vaccine against the tau peptide aa 294-305 coupled to keyhole limpet hemocyanin (KLH) with an Adju-Phos adjuvant. They claimed their vaccine to be directed against a structural determinant in disordered tau, which is essential for the pathological tau-tau interaction. As a disease-relevant model, the authors used a transgenic rat model expressing truncated human tau protein in the brain and spinal cord. Rats were immunized subcutaneously with 100 lg of the peptide conjugate. The study reproduced the reported beneficial effects (reduction of tau, reduction of tau phosphorylation, improvement upon sensorimotor functions) and featured additional safety and toxicology tests in different mammals such as rabbits and dogs. Adverse effects occurred in the form of a subcutaneous granuloma at the site of injection, corresponding to aluminum granulomas (Kontsekova et al. 2014) . Because of the lack of additional severe side effects, a clinical trial was initiated to test safety in humans (NCT 01850238, Phase I). In summary, active immunization against tau seems safe and effective in animals.
Active immunization against tau in humans At the moment, there are at least two ongoing Phase I studies, which are actively recruiting patients. An overview of all studies is provided in Table 1 . The tau fragment 294-305 is tested by Axon SE in healthy subjects under the clinical trial registration number NCT 01850238 (Phase I) and in mild to moderate AD patients under the clinical trial registration number NCT 02031198 (Phase I) (Yanamandra et al. 2013 ). The immunogen is linked to KLH trough a Nterminal cysteine and mixed with an aluminum hydroxide adjuvant. It recognizes disordered tau. The immunogen has been tested preclinically in rat and other animals as described above (Kontsekova et al. 2014) . The results of the study were recently published (Novak et al. 2017) . In that multicenter, randomized, double blind, placebo-controlled Phase I trial, 30 patients aged 50-85 years suffering from mild to moderate AD received three subcutaneous doses of AADvac1 at monthly intervals. The primary endpoint were drug tolerability and the safety profile. Furthermore, IgG response to the vaccine was measured. Reactions at the site of injection were the most common adverse effect, reported for 53% of patients; two patients withdrew from the study because of serious adverse events. Following the blinded, placebo-controlled phase of the study, participants were offered to enroll in an open label phase in which all patients received another three doses of AADvac1 at monthly intervals. Out of 30 patients treated, 29 responded by developing a strong IgG response. Cognition, albeit not being powered to support definite claims, remained stable over 6 months (Novak et al. 2017) . During the initial 12 weeks of the double blind phase, there was no difference in cognition between the placebo-treated and AADvac1-treated patients. Further studies are needed to estimate the effect on cognition.
In addition, AC Immune/Jansen has developed a vaccine with a liposomal adjuvant containing the phospho-tau peptide with phosphoserine 396/404 (Sigurdsson 2016) . The corresponding mouse experiment yielded promising results [see above, (Theunis et al. 2013] . According to the company's website, a clinical trial is being designed. According to our search, the study was not yet submitted to any of the clinical trials registration websites.
Passive immunization against tau in animals In addition to the described active immunization approaches, different passive immunization approaches are also being tested in mice. The first study by Eli Lilly used two different mouse models. The JNPL3 mice over-express human 0R4N tau with the P301L mutation under the mouse prion promoter. They develop symptoms at the age of 12th month. The P301S mice express tau with the P301S mutation under a thy1 promoter and develop severe motor symptoms at the age of 5-6 month. Both mice strains were immunized with two different antibodies (Chai et al. 2011) . The PHF antibody recognizes tau with phosphorylated serines 396 and 404, while the MC1 antibody recognizes conformationdependent early pathological tau conformations. Chai et al. measured less neurodegeneration in either mice model upon biochemical analysis, and better motor performance in P301S mice with each of the two antibodies compared to placebotreated mice. d 'Abramo et al. (2013) also investigated the effect of the anti-tau antibody MC1 in P301L mice and compared the effects with those of DA32, a pan tau antibody that recognizes the aa region 150-190 of tau with very high affinity. P301L mice were treated by intraperitoneal injections with 10 mg/kg body weight antibody once a week for 4 months in two cohorts of different ages. The authors observed a reduction of phosphorylated tau in the forebrain only in MC-1-treated mice without any influence on mice survival. They concluded that conformation specificity of the antibodies was of higher importance than affinity (d 'Abramo et al. 2013) . Still, the mechanism of action of how anti-tau antibodies target the intracellular NFT remained an open question. However, it was shown in vitro that intracellular tau fibrils were directly released into the medium. When tauexpressing cells were co-cultured with non-tau-expressing cells, the non-tau cells took up the fibrils. Kfoury et al. (2012) showed that tau monoclonal antibodies trapped tau fibrils in the extracellular compartment, thereby blocking aggregate propagation. With these data in mind, the same group tested three antibodies -HJ 8.5 (epitope aa 25-30), HJ 9.3 (epitope aa 306-320), and HJ 9.4 (epitope aa 7-13) -in P301S mice. The antibodies were administered intracerebroventricularly via an osmotic mini-pump continuously for 3 months. The antibodies reduced the formation of phosphorylated tau plaques in the mice brains in different brain regions (entorhinal cortex, amygdala, hippocampus CA1). The antibodies HJ 8 have been raised against human fulllength tau, while the antibodies named HJ 9 have been raised against mouse full-length tau. The mice showed no differences in locomotor activity, exploration, or sensorimotor functions, but showed differences in the conditioned fear response, which serves as a marker for associative learning. In a cell-based assay, antibody treatment reduced the uptake of tau fibrils into cells (Yanamandra et al. 2013) . Further testing of phospho-tau-recognizing antibodies has been done by Ittner et al. (Ittner et al. 2015) and Collin et al. (2014) . Ittner et al. tested two antibodies in two different mouse models. The antibodies pS404 mAb1 (IgG1) and pS404 mAb2 (IgG2) recognize pS404, which forms part of the PHF1 phosphoepitope. The authors used either pR5 or K3 mice. P301L tau transgenic pR5 mice develop late-stage tau phosphorylation and NFT-like structures in hippocampus and amygdala. K359I tau transgenic K3 mice show earlier tau phosphorylation and develop early memory and motor deficits. Mice were immunized with 10 lg/g body weight of antibody once a week intraperitoneally for 7 months with different age starting points depending on the model. Both mice developed a lower tangle burden and a reduced phosphorylation as detected with IgG2 antibodies (Ittner et al. 2015 ). Collin and colleagues described an antibody, called MAb86, against the phosphoepitope pS422 located at the C-terminus. They tested it in a triple transgenic AD mouse model (Collin et al. 2014) . These mice are homozygous for transgenic APP (Swe), presenilin 2 (N141I), and tau P301L expression. A treatment with this antibody for 16 weeks reduced tau pathology (Collin et al. 2014) . Mechanistically, MAb86 binds to the neuronal surface predominantly in lipid rafts. As the antibody is internalized to the lysosomes of neurons, the authors postulated an intracellular degradation of tau aggregates via lysosomal pathways in neurons.
In 2014, an interesting anti-tau antibody was developed and tested in two different mouse models (Castillo-Carranza et al. 2014b). Tau oligomer-specific monoclonal antibodies (TOMA) is a tau oligomer-specific monoclonal antibody that specifically recognizes oligomers but neither tau monomers nor fibrils. In a first study, TOMA was used to immunize JNPL3 mice at the age of 8 months, shortly before the expected disease onset at 12 months. Two ways of administration were compared: a single dose was administered intracerebroventricularly (1 lg TOMA) or intravenously (30 lg TOMA), respectively. A single dose reversed the phenotype of the mice biochemically and behaviorally for 60 days with either way of administration. Application of TOMA led to a rapid increase in serum tau oligomers within 1 h accompanied by a decrease of oligomeric tau in the brain, indicating a clearance from the brain to the periphery. There were no effects on NFT levels (Castillo-Carranza et al. 2014b). The authors proposed a model in which TOMA traps and neutralizes extracellular tau oligomers and promotes the reduction of intracellular and brain tau oligomers.
In a second study, TOMA proved efficacious in a different mouse model (Castillo-Carranza et al. 2014a) . Here, TOMA prevented tau seeding in 3-month-old mice expressing human tau homozygously after stereotactic hippocampal administration of brain-derived tau oligomers and prevented disease progression after a single IV (intravenous) dose for 1 month. In a second setting, biweekly TOMA injections prevented cognitive decline up to the age of 12 months (Castillo-Carranza et al. 2014a ). This study illustrates the need for an early therapeutic start: If the therapy is initiated before tau pathology is fully developed, it will not only improve symptoms but also reverse symptoms to a level comparable to wild-type mice.
Passive immunization against tau in humans
Four clinical trials are registered that test two different compounds that target tau via passive immunization (for a review, see (Sigurdsson 2016 ). An overview of all studies is provided in Table 1 . Bristol-Myers Squibb currently studies the compound BMS-986168. BMS-986168 targets the tau fragment 1-224 and should react with normal tau as well. It is administered intravenously. There are three studies registered for that compound. The first study assessed 65 healthy subjects (NCT 02294851, Phase I). Primary endpoints of this single ascending dose cohort study were safety, tolerability, and immunogenicity. The other two studies are being conducted in patients with PSP, a pure tauopathy. NCT 02460094 aims to assess pharmacodynamics of BMS-986168 on CSF extracellular tau concentrations in patients. The study is randomized, double blind, placebo-controlled, and uses multiple increasing dosages. The dosage scheme consists of BMS-986168 or matching placebo administered by IV injections, up to a maximum of three doses once every 4 weeks. Until the envisaged completion date in August 2017, a total of 48 patients are planned to be enrolled. Furthermore, an extension study has been initiated to followup the patients enrolled in the base study (NCT 02658916).
The second compound is C2N-E812 by C2N Diagnostics/ AbbVie (NCT 02494024, Phase I). Primary endpoints are safety and tolerability [maximum tolerated dose (MTD) within the specified dose range]. The double blind, placebocontrolled, single increasing dose study aims to enroll 32 patients with PSP. Four sequential cohorts are scheduled to receive increasing single doses of either C2N-8E12 or placebo intravenously. Out of every four patients enrolled, three patients will receive the drug and one will receive placebo. Study participants will be followed up for a minimum of 2 months post-treatment to monitor safety, tolerability, pharmacokinetics, and immunogenicity of C2N-8E12. No results are available yet. RG 7345, developed by Roche, is an additional humanized monoclonal antibody targeting the tau phosphoepitope pS422, but testing in humans has been discontinued according to information on alzforum.org (as of Juli 2017) (Collin et al. 2014).
Immunization in Parkinson disease
Characteristics of a-synuclein protein a-syn is a cytoplasmic protein composed of 140 amino acids encoded by the gene SNCA on chromosome 4. The physiological function is not entirely clear. Under pathological conditions, it aggregates to oligomers and fibrillary structures that are deposited in the neuronal cytoplasm (Lewy bodies), or in oligodendroglial cells. a-syn aggregates are primarily found not only in neurons [PD dementia with Lewy bodies (DLB)], but may also occur as glial cytoplasmic inclusions in oligodendrocytes (multiple system atrophy, MSA). a-syn consists of three different domains. The N-terminus (aa 1-60) contains all known, clinically relevant mutations of hereditary PD, which are A30P, E46K, H50Q, G51D, A53T, and A53E (Dehay et al. 2015) . The hydrophobic non-amyloid component (NAC) region (aa 61-95) is important for aggregation, oligomerization, and for building fibrils including b-sheet-like structures (Giasson et al. 2001 ). The C-terminal domain is proline-and aspartate/glutamate-rich (aa 96-140) and contains phosphorylation sites (Iwai et al. 1995; George 2002) . Most of the therapeutic antibodies described in the following sections bind in the C-terminal region. A detailed description of a-syn's protein structure as well as immunogens is provided in Fig. 3 .
Active immunization against a-syn in animals
There are different active immunization strategies against asyn, of which some use full-length a-syn and others use only parts of the full-length protein and design epitope-based vaccines. As learned from AD, the use of full-length protein as immunogen bears a high risk of inducing an a-syn-specific autoimmune response, comparable to the vaccination with AN1792 (Schenk et al. 1999) . Vaccination with AN1792 full-length protein induced aseptic meningitis in some of the treated AD patients (Robinson et al. 2004 ). In 2005, Masliah et al. (2005) reported that immunization in mice with fulllength a-syn led to a decline in a-syn deposition and reduced neurodegeneration. They used a heterozygous, transgenic mouse strain expressing human a-syn under the regulatory control of the platelet-derived growth factor b (PDGF b) promoter (Masliah et al. 2000) . Vaccinated animals Fig. 2 Structure of tau and overview of the immunogene targets. Tau has six isoforms translated in the brain. We depicted the longest splice variant with two inserts and four repeats. Tau has many phosphorylation sites; we showed the immunologically most studied phosposites S396 and S404. For immunogenes marked with an asterisk, no exact localization information was available.
developed a strong antibody response against a-syn and showed less a-syn-associated pathology and neurodegeneration in the brain (Masliah et al. 2005) . a-syn deposits in the presynaptic terminals were reduced, whereas synaptophysin expression was preserved. Furthermore, vaccinated animals exhibited less astrogliosis and higher microglial activity. The authors postulated that a-syn might be degraded through higher activity of the lysosomal pathways. In line with their hypothesis, the authors found a co-localization of a-syn deposits with lysosomal markers, for example, cathepsin D. The findings of Masliah and colleagues were surprising at first sight, because it was not clear how antibodies could reach the intracellular target protein a-syn. Today, however, the findings are well accepted and have been reproduced by other groups. Ghochikyan et al. (2014) used a different strategy. They developed three peptide-based epitope vaccines of short a-syn fragments fused to a B-cell-stimulating tetanus toxoid fragment P30. They immunized C57BL/6 immunocompetent laboratory mouse strain mice without any specific parkinsonism gene background. Specificity of the antibodies was assessed by enzyme-linked immunosorbent assay (ELISA). Immunization induced a humoral immune response. In addition, sera of immunized mice recognized Lewy bodies and Lewy neurites in confirmed human DLB brain tissue slices and a-syn upon western blotting of human brain homogenates. This confirms that these antibodies recognize their epitope in patients' tissue.
A very interesting approach has been chosen by Mandler and colleagues (Mandler et al. 2014 (Mandler et al. , 2015 . They developed the AFFITOME technology platform that is based on short epitope peptides expressed by a phage display library. Screening with a specific monoclonal antibody against the target protein selects suitable immunogenic peptides. The AFFITOPE peptides are too short to induce a specific T-cell response (Mandler et al. 2014 (Mandler et al. , 2015 . This platform was already successfully used in the generation of AD vaccines. In the case of PD, the phage display library was screened with monoclonal antibodies that specifically bind to the Cterminus of human a-syn. The most effective peptide was AFF1. AFF1 has been tested in three different mouse models in two separate studies. The first two mouse models expressed human wild-type a-syn either under a PDGF promoter or under an mThy1 promoter (Mandler et al. 2014) . The mouse strain with the PDGF promoter developed a-syn aggregates in the temporal cortex and hippocampus, resembling DLB pathology in humans including behavioral deficits. The mice over-expressing a-syn under the mThy1 promoter showed a-syn aggregates in cortex and subcortical regions with prominent axonal pathology that resembled PD and PD with dementia, including motor deficits. Vaccination started at a time point when only minor PD-like alterations were detectable: at 3 months age in mThy1 a-syn transgenic mice and at 6 months in PDGF asyn transgenic mice. In both models, the authors found a specific and robust humoral response induced by vaccination with AFF1 in both plasma and CSF. Immunization with AFF1 resulted in decreased accumulation of a-syn oligomers in axons and synapses. Neurodegeneration was reduced as assessed by staining of NeuN-positive neurons. Behaviorally, AFF1-immunized PDGF a-syn transgenic mice performed better with respect to memory (tested with the water maze) and motor function (tested with the modified coat hanger test). Their performance levels were rescued to a level equal to non-transgenic mice. AFF1-mmunized mThy1 a-syn transgenic mice showed reduced motor deficits compared to the vehicle-treated transgenic control group. Mechanistically, Mandler and colleagues explained these clinical and histopathological reductions by intensified microglial a-syn clearance and a shift in cytokine production toward an anti-inflammatory response, as investigated by a mouse cytokine panel array.
A second study yielded comparable results in a third mouse model mimicking MSA. In these mice, a-syn was controlled by the promoter myelin basic protein leading to expression in oligodendrocytes (Mandler et al. 2015) . Vaccination with AFF1 resulted in decreased accumulation of asyn, reduced demyelination in the neocortex, striatum and corpus callosum, and reduced neurodegeneration compared Fig. 3 Structure of aSyn and overview of the immunogen targets. aSyn consists of three immunologically relevant epitopes: The C-terminal, the mid-terminal NAC region and the N-terminal epitope. Immunogens in italics recognize also Ab oligomers or fibrils. The ones marked with an asterisk, no exact localization information was available. aSyn protein structure pictogram was adapted from Riek (Riek & Eisenberg 2016) .
to the vehicle-treated, transgenic control group. Mechanistically, these effects were associated with microglial activation and reduced spreading of a-syn to astroglial cells.
Ugen and colleagues developed a vaccine based on dendritic cells sensitized with a-syn (Ugen et al. 2015) . They vaccinated transgenic mice that expressed the human disease-associated A53T mutation of a-syn with bone marrow-derived dendritic cells repeatedly, starting at the age of 14 weeks with four injections every 2 weeks and to booster injections at the age of 30 weeks and 52 weeks. These cells were sensitized with three peptides with predicted B-cell epitopes, resulting in so-called peptide-sensitized dendritic cells (PSDC). PSDC elicit a specific humoral immune response by interacting with the host's cellular immune system. Rotometric locomotor performance at the age of 8 and 17 months showed that PSDC-treated animals restored their mobility by the age of 17 months. According to the authors, this effect was probably mediated by lower levels of the pro-inflammatory cytokine IL1-a (Ugen et al. 2015) . In humans, vaccines on the basis of dendritic cells are in clinical use for the treatment of hormone-resistant metastatic prostate cancer (Wesley et al. 2012) .
Aside from cell-based strategies, there are also DNA vaccination strategies. The first DNA vaccination against asyn was developed by Chen and colleagues (Chen et al. 2013) . This a-syn-expressing DNA construct led to specific anti-a-syn antibody responses. The vaccination reduced cell death of TH-positive neurons in the substantia nigra and led to better performance in motor functions. In their very comprehensive review, Schneeberger et al. (2016) reported on a-syn peptides fused to virus-like particles that were developed by the Jenner Institute and Declion Pharmaceuticals. These virus-like particles were prepared for preclinical and clinical testing. To date, no further information on this approach is publicly available (Schneeberger et al. 2016) .
Active immunization against a-syn in humans All clinical studies with active immunization against a-syn employ AFFITOPES by AFFiRiS (Mandler et al. 2014 (Mandler et al. , 2015 . An overview of all studies is provided in Table 1 . Currently, five clinical studies are registered. The first clinical trial tested PD01A (NCT 01568099, Phase I). The corresponding AFFITOPE peptides are fused to KLH and accompanied by the adjuvant aluminum oxyhydroxide. The vaccine was administered subcutaneously. Thirty-two patients suffering from early PD were enrolled and pseudorandomized into groups of 12 patients with four injections of either low or high dose vaccination, and eight patients into the placebo group (Kalia et al. 2015; Schneeberger et al. 2016) . Follow-up was 1 year. The primary endpoint was defined as occurrence of any adverse or severe adverse effect; secondary endpoints were immunogenicity and clinical activity including motor and non-motor symptoms as well as change in biological and radiological biomarkers. The investigators reported a significant difference in disease progression between the placebo and treatment groups in the absence of adverse events [Volc et al., in preparation, as cited by (Schneeberger et al. 2016) ]. AFFITOPE-specific antibodies against the vaccine peptide were detected in the serum of half of the patients, and in a minority of patients these were also detected in the CSF (Kalia et al. 2015) . This initial study was followed by two extension studies. One study assessed safety and clinical activity of one additional booster immunization in the same group of patients (NCT 02216188, Phase I); the other is an observational Phase Ib study that followed up the patients to assess safety and efficacy (NCT 01885494, Phase Ib). Both studies were completed in January 2017, though the results are not yet published.
AFFiRiS also developed another vaccine called PD03A. PD01A and PD03A slightly differ in the specificity of their induced antibodies and their clinicobiological activity in the different disease models. As mentioned above, both PD01A and PD03A are fused to KLH, contain aluminum oxyhydroxide, and are administered subcutaneously. PD03A is currently being tested in two studies in patients with PD and MSA, respectively. In a trial in early PD that started in December 2014, 36 patients at early disease stage were pseudo-randomized to one of the three equal groups that received either low (five injections of 15 lg over a period of 36 weeks) or high (five injections of 75 lg over a period of 36 weeks) doses of PD03A, or placebo, respectively (NCT 02267434, Phase I). Inclusion criteria encompassed early PD diagnosed < 4 years ago, and meeting both Hoehn & Yahrs Stages I/II as well as United Kingdom Parkinson 0 s Disease Society Brain Bank Criteria. Furthermore, dopamine transporter single photon emission computed tomography and magnetic resonance imaging were required to be consistent with the diagnosis of PD. Patients received the first four vaccinations every 4 weeks and the final vaccination 36 weeks later as a final boost.
The AFFITOPE vaccinations have shown promising results also in an MSA mouse model as mentioned above (Mandler et al. 2015) . The second trial included patients with an early diagnosis of MSA, defined as possible or probable MSA according to the Gilman consensus criteria 2008 and onset of MSA symptoms < 4 years before study enrolment (Gilman et al. 2008) . In this trial, both substances PD01A and PD03A were tested in 30 patients, assessing safety and therapeutic activity as primary endpoints (NCT 02270489, Phase I). Dosage was analogous to the PD01A regimen in early PD. Pending more definite results on the substances' efficacy, it might be possible to offer different vaccines to both PD and MSA patients.
Passive immunization against a-syn in animals A plethora of compounds for passive immunization against a-syn has been developed and tested in mice. The first to show positive effects of passive immunization against a-syn was Masliah et al. (2011) . His group immunized transgenic animals expressing human wild-type a-syn under a PDGF promoter (PDGF-hu-wt-aSyn mice) using a human fulllength a-syn IgG1 antibody. The antibody targeted the epitope aa 118-126 (9E4). It was applied intraperitoneally once a week for 6 months with a dose of 10 mg/kg. Histologic examination revealed a reduction of the Cterminally truncated a-syn aggregates in treated mice. The molecular changes were reflected on a behavioral level by improved motor and cognitive performance in treated mice. Further biochemical analysis showed, that the antibody was mainly located extracellularly, while the target a-syn was located intracellularly together with an increase in the activity of cathepsin D, generally interpreted as a marker for protein degradation. This hinted at a first mechanistic link in terms of an increased lysosomal degradation of a-syn antibody complexes (Masliah et al. 2011) .
Later, the same group immunized transgenic PDGF-hu-wtaSyn mice with a different C-terminal antibody AB274 (epitope aa 120-140, mIgG2a) (Bae et al. 2012) . Immunohistochemistry and immunofluorescence showed an uptake of antibodies into vesicles of microglia. This uptake was Fc receptor dependent and specific to microglia. It was absent in neuronal cells or astrocytes. Additionally, inflammatory cytokines such as TNFa and interleukin 6 were reduced. Treatment prevented spreading of a-syn from neurons to astroglia, and ameliorated neurodegeneration. In line with the other reported studies, treatment with antibodies reduced motor symptoms compared to IgG-treated, transgenic control mice. In 2014, the group reported the results from three additional antibodies (1H7, 5C1, and 5D12) applied to an mThy1 wild-type a-syn transgenic mouse model with the above described immunization scheme. The antibodies were obtained by immunization against C-terminal a-syn peptides close to the epitope aa 118-126. These residues also constitute for the epitope of the antibody 9E4 (Games et al. 2014) . The epitope of a fourth antibody, 1H7, was directed toward the Nterminus (aa 91-99). Animals were killed at the age of 1 year. The authors observed a reduction of the accumulation of Cterminally truncated a-syn as well as a reduction of the axonopathy. Synaptic protein levels were restored. Treatment prevented the loss of TH at the striatal synapses. Again, mice also improved functionally upon motor tests. With the exception of 5D12, all antibodies were of equal efficacy. Games et al. hypothesized that this might be a consequence of the more linear epitope targeted by 5D12, in contrast to the conformational epitopes targeted by the other three antibodies. In addition to the promising findings from the Masliah group, another group produced similar results with a C-terminal antibody Ab47, which targets epitope aa 121-127 (Lindstrom et al. 2014) . Ab47 targets specifically a-syn protofibrils, therefore targeting a conformational n-mer variant of the protein (for further discussion, see Immunizing against the right epitope). They used a transgenic mouse expressing the human pathologic A30P variant of a-syn under a Thy1 promoter and injected the antibody intraperitoneally at a dose of 10 mg/kg body weight once a week for 14 weeks. Treated mice performed better in motor tests than transgenic mice treated with a non-specific antibody. Biochemically, lower levels of protofibrils and oligomers were present in the brainstem and spinal cord of treated mice.
Lee and colleagues generated an antibody called Syn303 that targets a N-terminal epitope in a-syn (aa 1-5) (Tran et al. 2014) . They modeled PD by unilateral, stereotactic injection of synthetic preformed fibrils into the striatum, which usually leads to a transmission of the fibrils to the other hemisphere in the course of the disease. The immunization scheme was 10 mg/kg body weight once a week for 26 weeks. Treated animals showed better motor performance, less dopaminergic neuron loss in the substantia nigra, less overall histologic disease stigmata, and decreased transneuronal a-syn transmission compared to control animals. Binding efficacy of a-synspecific antibodies was restricted to conformational epitopes, but not necessarily to the C-terminus of a-syn (Tran et al. 2014) . Shahaduzzaman et al. (2015) evaluated a second Nterminal antibody. They generated two antibodies, one (AB1) directed against a N-terminal epitope, the other (AB2) against a midpart a-syn epitope. They immunized rats intraperitoneally with 1 mg of antibody per rat after stereotactic injection of an AAV9-CBA-h-wt aSyn vector into the substantia nigra. AB1 reduced TH-positive neurons and neuroinflammation. By contrast, the AB2 antibodies only led to a significant reduction in neuroinflammation.
Passive immunization against a-syn in humans There are at least three studies with two different compounds investigating passive immunization in humans. An overview of all studies is provided in Table 1 . The monoclonal antibody PRX002 by Prothena is a humanized version of the mouse antibody 9E4 administered via IV infusions. It was tested in 40 healthy subjects (NCT 02095171, Phase I) -assigned to five cohorts with six patients each -with increasing doses (0.3; 1; 3; 10; 30 mg/kg body weight). Primary outcome parameters were safety and tolerability as well as pharmacokinetic parameters. No adverse events were reported and a-syn levels decreased in a dose-dependent manner in the participants' serum (Kalia et al. 2015; Bergstrom et al. 2016) .
A second study examined the efficacy of PRX002, applied at multiple increasing doses in an analogous dosage scheme to 60 patients with mild to moderate idiopathic PD (NCT 02157714, Phase I). Primary outcome parameters were safety and tolerability as measured by the number of adverse events, and different pharmacokinetic parameters. Secondary outcome parameters included multiple clinical and exploratory biomarkers. PRX002 had a favorable safety and tolerability profile with no immunogenicity, as well as favorable pharmacokinetics (Schenk et al. 2017) . Neither serious or adverse events nor dose-limiting toxicities were reported. A significant dose-dependent reduction in free serum a-syn occurred within 1 h after administration of PRX002. The authors conclude that serum a-syn can be modulated safely in a dose-dependent manner and that their findings support a continued development of PRX002.
The second compound BIIB054 by Biogen is a monoclonal antibody against a-syn isolated from a B-cell library from healthy elderly which were stimulated with a-syn analogously to aducanumab in AD. Thus, BIIB054 resembles closest to the concept of nAbs. This antibody is tested in a Phase I study in 40 healthy subjects treated with multiple increasing doses analogously to PRX002. Primary outcome parameters include severe and adverse effects as well as a cognitive score (Montreal Cognitive Assessment) and a suicidality score (Columbia Suicide Severity Rating Scale). Secondary outcome parameters include total a-syn in serum (NCT 02459886, Phase I) (Bergstrom et al. 2016; Valera et al. 2016 ). This study is currently ongoing (Weihofen et al. 2016) and recruiting patients.
Discussion
Choosing the best vaccination strategy Immunization strategies are a feasible option in the treatment of neurodegenerative disorders. However, several key points need to be considered. AD and PD are both associated with a long asymptomatic period, followed by prodromal symptoms. For any disease-modifying therapy to be successful in these disorders, it needs to be started early in the asymptomatic period, and this necessitates identification of patients at risk. Currently, prodromal AD patients can be identified via neuropsychiatric tools and biomarkers such as CSF measurement of tau and Ab or amyloid PET scans, which enables a better stratification to include suitable patients into clinical trials.
In order to identify prodromal PD patients with a high likelihood, the Movement Disorder Society proposed a catalog of research criteria which include several clinical symptoms and clinical signs including RBD. Recently, Doppler and colleagues demonstrated a-syn deposits in skin biopsies in patients with RBD (Doppler et al. 2017) . This technique might soon be used to identify prodromal PD patients, enroll them into vaccination trials at a much earlier time point than has been possible so far, and possibly allows monitoring of disease progression. Nevertheless, the need for better monitoring of disease progression in addition to clinical scores is undebated. In this review, we discussed both active and passive immunization. Active immunization has some advantages over passive immunization. Because of the chronic character of the two diseases, it is easier and economically more efficient to actively immunize the patient to trigger perpetual production of the protective antibodies. The vaccine needs to be administered only few times, usually subcutaneously. Some booster vaccinations may be necessary in the further course; nevertheless, application intervals are considerably long. Unfortunately, elderly people do not respond to vaccination as efficiently as pediatric cohorts. This is well documented for influenza immunization (Goodwin et al. 2006) . Active immunization in the elderly requires balancing sufficient stimulation of the senescent immune system with the necessity to avoid overshooting Th1 stimulation, which promotes recognition of self-antigens. Passive immunotherapy can avoid some of these problems. It delivers the protective antibody to the immune system, but it requires repeated i.v. injection at short intervals (in the range of several weeks) over the entire long course of the disease. Passive immunotherapy is divided into different types: IVIg are isolated from blood of healthy, usually young donors and subsequently commercially purified. They also contain nAbs against a variety of autoantigens. Even though several studies to treat AD with IVIg were undertaken, the majority was unconvincing (Dodel et al. 2010 . Despite the protective potential of nAbs, the amount of antibodies against Ab might not have been concentrated enough to induce a measurable effect. The safety of long-term IVIg treatment is well documented through its regular use in patients with various other diseases such as chronic inflammatory demyelinating neuropathy or inherited immunodeficiency syndromes. Hypothetically, even if an effect of IVIg was proven in AD patients, IVIg stocks worldwide would not last in case of high treatment coverage. Theoretically, development of antibodies against the poly-or monoclonal treatment antibodies and loss of efficacy might be a problem of long-term passive immunization. Monoclonal antibodies can be produced without the need for blood donors. Owing to the advantages and the popularity of antibody treatment in general in many fields in targeted medicine, it is plausible that costs for production might fall in the future. For AD, data for the monoclonal antibody aducanumab are currently most auspicious. Aducanumab was not generated generically by immunizing a host species with full-length or fragmented proteins, but isolated from stimulated B-cells of healthy old subjects.
Immunizing against the right epitope At the moment, it is unclear what influences the antibody's efficiency in binding its target and even worse, it is not clear, what the best target could be in terms of addressing mono-or various forms of multimers. There are many experimental antibodies available that bind extracellular Ab. It seems that most of the antibody recognition 'motifs' depend on a protein structure rather than on a primary sequence. This conformational specificity also holds true for the intracellular proteins tau and aSyn. A low-affinity antibody against a conformational epitope, showing efficacy in clearing tau pathology, worked effectively in a mouse model, whereas a high affinity antibody toward total tau did not (d 'Abramo et al. 2013) . The most studied epitope in tau was phosphoserine 496/404 (pS496/404). This phosphorylation site promotes a pathological conformational change inside tau (Jeganathan et al. 2008) . Nevertheless, tau pS496/404 is not the only immunogenic epitope. At least five additional immunogenic epitopes are described, which are scattered along the fulllength tau protein (Selenica et al. 2014) . The target protein recognition is most likely triggered by a common conformation rather than through a specific sequence detection. This is in line with data from our group, showing cross-reactivity of autoantibodies (Albus et al. 2014) . For all mentioned disorders, it is currently unclear which form of the protein should be targeted. Many vaccines have been generated against epitopes on a protein level or even subprotein level, using peptides as the immunogen. This method leaves out the propensity of Ab, tau, and a-syn to form altered conformation aggregates. The formation of dimers, oligomers, multimers, and ultimately fibrils increases the number of potential epitopes. Ideally, antibodies will recognize an oligomeric structure rather than a specific amino acid sequence. This may lead to recognition of more than one pathogenic species. In our own experiments, this was shown for Ab and the prion peptide. Ab was detected by naturally occurring antibodies against the prion peptide as well as by nAbs-a-Syn and nAbs-Ab (Albus et al. 2014) . This preliminary result needs further validation in animal experiments. For a-syn, the antibody Ab47 represents an exception: Ab47 targets protofibrils, a term that subsumes all large oligomers (Lindstrom et al. 2014) . Nevertheless, the effects were similar to antibodies targeting monomeric a-syn.
On their way to assemble into stable and insoluble fibrils, most proteins form metastable, prefibrillar oligomeric species (Melki 2017) . These prefibrillar oligomers are considered to be the most toxic as they were shown to impair membrane integrity and permeability necessary for synaptic function (Danzer et al. 2007; Winner et al. 2011) . The secondary structure of distinct proteins seems to play an important role in the pathogenesis of different taupathies or synucleinopathies, establishing the concept of strains (Melki 2017; Stopschinski and Diamond 2017) . When mice are inoculated with tau proteins of various conformations isolated from patients' brain tissue, these conformation patterns persist repeated mouse inoculations and form unique pathological patterns (Sanders et al. 2014) . In rats, different well-defined a-syn assemblies such as oligomers, ribbons, and fibrils caused Lewy body-like structures upon intracerebral inoculation, and led to distinct histopathological and behavioral phenotypes (Peelaerts et al. 2015) . In summary, strains partly explain the extensive clinicopathological variability in taupathies and synucleinopathies (Stopschinski and Diamond 2017) . Currently, it is still under debate which species is best suited for vaccination strategies. Nevertheless, the concept of strains offers new epitopes to target with vaccination therapies.
Identifying the most crucial mechanism Today, the effect of antibodies targeting intracellular proteins is well established. Nevertheless, the clear decrease in a-syn deposits in the brain of antibody-treated mice was quite surprising in 2005 when Masliah et al. (2005) presented their first data on immunization against a-syn. Several hypotheses have been postulated on the mechanisms of action, but not all are well understood. According to the Braak hypothesis, asyn spreads from cell to cell in a prion-like fashion. Indeed, Jang and colleagues could show that a-syn is secreted from neuronal cells by unconventional exocytosis, which is independent from the endoplasmic reticulum/Golgi apparatus (Jang et al. 2010 ). The secreted a-syn was mostly oligomeric (Kim et al. 2013 ) and secretion was enhanced by blocking of proteasome and lysosome inhibitors or autophagy inhibitors (Jang et al. 2010; Lee and Lee 2016) . Extracellular a-syn aggregates were internalized by neurons and glial cells. Antibodies also lead to a reduced accumulation of extracellular a-syn in neurons and glia (Bae et al. 2012) . Passive immunization leads to a reduced cell-to-cell propagation of a-syn (Games et al. 2014 ) and transmission of a-syn between cells seemed to be blocked in cell culture and animal models (Tran et al. 2014) . For tau, a prion-like spreading is discussed. Cells transfected with tau release fibrils into the medium, which are recognized by tau antibodies (Kfoury et al. 2012; Yanamandra et al. 2013) . Additionally, anti-tau antibodies seem to not enter neuronal cells (d 'Abramo et al. 2013 ). Analogously to a-syn, intracellular clearing of tau is supposedly mediated via enhanced endosomal/lysosomal activity (Sigurdsson 2016) .
The cell population with highest phagocytic activity in the brain is that of the microglia. They supposedly play a key role in the antibody-aided clearance of proteinopathies. Research in the AD field focused on the role of microglia in the past years. The discovery that TREM2, an immune receptor that is found in brain microglia, is a risk factor for non-familial Alzheimer disease genetically linked AD and microglial dysfunction (Guerreiro et al. 2013; Colonna and Wang 2016) . The microglial response during disease sustains survival or otherwise promotes cell degeneration. Initially proposed for macrophages only, the concept of M1/M2 polarization can in part explain both beneficial as well as neurotoxic effects of microglia in neurodegenerative disorders (Heneka et al. 2015) . The M1 polarization is characterized by the expression of inflammatory and cytotoxic cytokines as TNF-a, interleukin 6, IL-12, promotes antigen presentation, and cellular immune response. The M2 polarization is characterized by the expression of non-inflammatory cytokines as IL-10 and IL-1, and promotes phagocytosis and tissue remodeling. In the case of Ab, M2-polarized microglial cells are able to clear soluble and fibrillar Ab. Therefore, the M2 state seems to reduce toxic effects and enhance the phagocytic activity toward Ab (McGeer and McGeer 2015) . By contrast, continuous Ab stimulation can lead to an inflammatory microglial response resulting in neurotoxicity (Gold and El Khoury 2015) . The role of microglia in AD is ambiguous.
Phagocytosis is considered beneficial in preventing spread of Ab and reducing Ab load. On the other hand, the constant secretion of pro-inflammatory cytokines contributes to neurodegeneration and thus progression of the disease. It was shown that nAbs increase phagocytosis and reduce secretion of pro-inflammatory cytokines, both of which is considered beneficial (Gold et al. 2013; Mengel et al. 2013) . The intracellular inflammasome, especially NLRP3, seems to play a critical role in the pathogenesis of AD (Heneka et al. 2013) , but its regulation is not well understood. Interestingly, dopamine seems to inhibit the NLRP3 inflammasome via dopaminergic receptors, that are expressed on microglia and other immune cells (Sarkar et al. 2010; Yan et al. 2015) . Romero-Ramoz reviewed the effect of dopamine on microglia and mononuclear peripheral immune cells and how this regulation is affected in PD (Romero-Ramos et al. 2014) . They proposed the need to prime the immune system to restore natural tolerance against a-syn in Parkinson's disease, simultaneously including B and T cells, so that T cells can reprogram microglia activation to a beneficial pattern and B cell/IgG can help neurons cope with the pathological forms of asynuclein (Romero-Ramos et al. 2014). For tau, microglial stimulation might be one key to reduce aggregate burden, as indicated by an uptake of antibody-marked tau fibrils via the Fc receptor (Sigurdsson 2016) . In contrast to the Fc receptor located at the extracellular surface of the cell membrane, an Fc receptor variant located in the cytosol named TRIM21 was shown to neutralize tau seeding (McEwan et al. 2017) . For a-syn, antibody treatment stimulated microglial clearance of extracellular a-syn (Lee et al. 2008 ) and uptake into microglia was mediated by the Fcc receptor, congruent with the data for tau (Bae et al. 2012) . The concept of tau or alpha-synuclein spreading and uptake by neighboring cells as a driving force in disease progression positions microglia as the main cell that can clear protein aggregates efficiently (Sanchez-Guajardo et al. 2015) .
Besides these effects of cellular players in the brain, the possibility of a peripheral clearance of protein-antibody complexes from the brain was widely discussed at least for Ab as 'the peripheral sink theory'. Demattos and colleagues postulated this hypothesis after describing a serum Ab peak after peripheral administration of a monoclonal antibody to Ab (DeMattos et al. 2002) . This effect was also described for tau (Castillo-Carranza et al. 2014b ). According to this interpretation, the antibodies decrease the peripheral protein concentration equilibrium that leads to a shift of soluble brain protein species to the periphery and subsequent a clearance of brain protein deposits. Therefore, it can be assumed that antibodies targeting only peripheral Ab may be sufficient for its clearance. Nevertheless, the proportions of antibodies that cross the blood-brain barrier seem to be important. Thus, antibodies targeting the species directly in the brain are currently considered to be more effective. In both cases, however, treatment in early disease stages will be important.
Conclusion
Altogether, many groups have shown that antibodies targeting intracellular proteins as tau and a-syn can reduce pathologic protein accumulations and improve behavioral and motor outcome parameters in mice. While the exact mechanism remains obscure, it may in part be based on extracellular binding of the antibodies to released protein, interrupting the prion-like spreading. In humans, the effects on primary and secondary outcome parameters such as cognition in AD and motor performance in PD and a reduction of disease progression remain to be verified. Much work will be required to elucidate the mechanisms of action, and to improve our understanding of this rapidly emerging field of experimental therapies. Nevertheless, the results presented give cause for hope that neuronal decline might be halted in patients suffering from neurodegenerative disorders.
